BrightSpring Health Services, Inc.·4

Mar 6, 7:45 PM ET

Phipps Jennifer A 4

Research Summary

AI-generated summary

Updated

BrightSpring (BTSG) CFO Jennifer Phipps Sells 35,000 Shares

What Happened

  • Jennifer A. Phipps, Chief Financial Officer of BrightSpring Health Services (BTSG), exercised options and sold shares around a registered offering. On March 4, 2026 she exercised 35,000 option-derived shares at $6.37 per share (cost $222,950) and sold those 35,000 shares at $41.15 per share for proceeds of $1,440,250 (sale made pursuant to a registered public offering that closed March 4, 2026).
  • The filing also shows multiple award/vesting events: RSUs granted (53,384 RSUs on March 5, 2026 that vest in three equal annual installments beginning Jan 25, 2027) and several derivative/share issuances tied to the vesting of prior performance options (including vesting of 2019 and 2020 performance options, which became fully vested as of March 4, 2026).

Key Details

  • Transaction dates and prices:
    • March 4, 2026: Exercised 35,000 shares @ $6.37 (paid $222,950); sold 35,000 shares @ $41.15 (proceeds $1,440,250). Sale occurred via registered public offering (footnote F1).
    • March 5, 2026: Granted 53,384 RSUs @ $0.00 (footnote F2), vesting over three years starting Jan 25, 2027.
    • Filing reports additional derivative/award entries (35,331; 5,888; 130,860 shares) tied to vested performance-based options (footnotes F3–F6).
  • Shares owned after the transactions: Not specified in the Form 4 excerpt provided.
  • Notable footnotes:
    • F1: Sale was part of a registered offering that closed March 4 at $41.15 (pre-fees).
    • F2: RSUs vest in three equal annual installments beginning Jan 25, 2027; each RSU converts to one share upon settlement.
    • F3–F5: Reflect vesting of previously awarded performance options (2019 and 2020 awards); those performance options became fully vested on March 4, 2026.
    • F6: Some options vest in three equal annual installments starting Jan 25, 2027.
  • Timeliness: Form 4 was filed March 6, 2026 reporting transactions through March 5, 2026 — the filing appears timely.

Context

  • The sequence (exercise at $6.37 followed by an immediate sale at $41.15 in a registered offering) effectively monetized vested options and generated a significant cash proceeds event for the insider; this was not a routine open-market sale but part of a public offering (see F1).
  • The RSU grants and the vesting of older performance options reflect compensation/award activity (vesting of prior grants and new RSU awards), not necessarily a new purchase signal. As always, awards and vesting can be for retention/compensation rather than an endorsement of near-term share performance.